DAILY LEAD
MoESurv: A Zero-Sample and Transferable Survival Prediction Framework for Rare Cancers Using Mixture of Experts.
Observation and source date: 22 July 2026. This edition uses PubMed Date-Publication records; that field is not a peer-review completion date.
MoESurv separates shared and cancer-specific signals with a mixture of experts; the authors report a four-point mean C-index gain across seven rare TCGA cancers plus external validations.
Performance and stratification are not yet evidence of clinical benefit.